Acute dexamethasone-induced increase in cardiac lipoprotein lipase requires activation of both Akt and stress kinases

American Journal of Physiology - Endocrinology and Metabolism

Volumn 295, Issue 1, 2008, Pages

  Kewalramani, Girish ^a   Puthanveetil, Prasanth ^a   Min, Suk Kim ^a   Wang, Fang ^a   Lee, Vivian ^a   Hau, Nathania ^a   Beheshti, Elham ^a   Ng, Natalie ^a   Abrahani, Ashraf ^a   Rodrigues, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Actin cytoskeleton; Adenosine monophosphate activated protein kinase; Fatty acids; Heart

Indexed keywords

ACTIN; ADENYLATE KINASE; DEXAMETHASONE; F ACTIN; HEAT SHOCK PROTEIN 25; INSULIN; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; AMP ACTIVATED PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; GLUCOCORTICOID; HEAT SHOCK PROTEIN; HSPB1 PROTEIN, RAT; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL SURFACE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; GENOMICS; HEART MUSCLE CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MALE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HEART; HEART MUSCLE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RAT; WISTAR RAT;

ACTINS; ANIMALS; DEXAMETHASONE; ENZYME ACTIVATION; GLUCOCORTICOIDS; HEART; HEAT-SHOCK PROTEINS; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; MALE; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; MYOCARDIUM; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR;

EID: 50349096412     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00004.2008     Document Type: Article

References (48)

1. An D, Pulinilkunnil T, Qi D, Ghosh S, Abrahani A, Rodrigues B. The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288: E246-E253, 2005.
2. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291: H1489-H1506, 2006.
3. Augustus AS, Kako Y, Yagyu H, Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284: E331-E339, 2003.
4. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9: 1069-1075, 2003.
5. Block NE, Buse MG. Effects of hypercortisolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am J Physiol Endocrinol Metab 256: E39-E48, 1989.
6. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 67: 529-534, 2002.
7. Buttgereit F. Mechanisms and clinical relevance of nongenomic glucocorticoid actions. Z Rheumatol 59: II/119 -123, 2000.
8. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 138: RE9, 2002.
9. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225-233, 2005.
10. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822, 2001.
11. Dai T, Natarajan R, Nast CC, LaPage J, Chuang P, Sim J. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 69: 806-814, 2006.
12. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30: 1000-1007, 1981.
13. Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 321: 707-712, 1997.
14. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060-1068, 1989.
15. Ewart HS, Severson DL. Insulin and dexamethasone stimulation of cardiac lipoprotein lipase activity involves the actin-based cytoskeleton. Biochem J 340: 485-490, 1999.
16. Ewart HS, Carroll R, Severson DL. Lipoprotein lipase activity in rat cardiomyocytes is timulated by insulin and dexamethasone. Biochem J 327: 439-442, 1997.
17. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002.
18. Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ. Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 91: 2020-2030, 1993.
19. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23: 1112-1119, 2001.
20. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110: 1251-1257, 2004.
21. Jessen N, Goodyear LJ. Contraction signaling to glucose transport in skeletal muscle. J Appl Physiol 99: 330-337, 2005.
22. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A, Pulinilkunnil T, Shrama V, Wambolt RB, Allard MF, Innis SM, Rodrigues B. AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 42: 333-342, 2007.
23. Kim M, Kewalramani G, Puthanveetil P, Lee V, Kumar U, An D, Abrahani A, Rodrigues B. Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependant actin cytoskeleton organization. Diabetes 57: 64-76, 2007.
24. Kovacic C, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278: 39422-39427, 2003.
25. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513-17520, 1995.
26. Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 27: 361-370, 2004.
27. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol 33: 1065-1089, 2001.
28. Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL. Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density lipoprotein-cholesterol levels. Proc Natl Acad Sci USA 96: 3165-3170, 1999.
29. Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR, 3rd, Young LH. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 97: 872-879, 2005.
30. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52: 1627-1634, 2003.
31. Opie LH. Cardiac metabolism - emergence, decline, resurgence. Part II. Cardiovasc Res 26: 817-830, 1992.
32. Phillips DI, Barker DJ, Fall CH, Seckl JR, Whorwood CB, Wood PJ, Walker BR. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrinol Metab 83: 757-760, 1998.
33. Pillarisetti S, Paka L, Sasaki A, Vanni-Reyes T, Yin B, Parthasarathy N, Wagner WD, Goldberg IJ. Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272: 15753-15759, 1997.
34. Pulinilkunnil T, An D, Ghosh S, Qi D, Kewalramani G, Yuen G, Virk N, Abrahani A, Rodrigues B. Lysophosphatidic acid-mediated augmentation of cardiomyocyte lipoprotein lipase involves actin cytoskeleton reorganization. Am J Physiol Heart Circ Physiol 288: H2802-H2810, 2005.
35. Pulinilkunnil T, Rodrigues B. Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease. Cardiovasc Res 69: 329-340, 2006.
36. Qi D, An D, Kewalramani G, Qi Y, Pulinilkunnil T, Abrahani A, Al-Atar U, Ghosh S, Wambolt RB, Allard MF, Innis SM, Rodrigues B. Altered cardiac fatty acid composition and utilization following dexamethasone-induced insulin resistance. Am J Physiol Endocrinol Metab 291: E420-E427, 2006.
37. Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, Brownsey R, Wambolt R, Allard M, Rodrigues B. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 53: 1790-1797, 2004.
38. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 292: E654-E657, 2007.
39. Rodrigues B, Cam MC, Jian K, Lim F, Sambandam N, Shepherd G. Differential effects of streptozotocin-induced diabetes on cardiac lipoprotein lipase activity. Diabetes 46: 1346-1353, 1997.
40. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 48: 2119-2130, 2005.
41. Sambandam N, Abrahani MA, St Pierre E, Al-Atar O, Cam MC, Rodrigues B. Localization of lipoprotein lipase in the diabetic heart: regulation by acute changes in insulin. Arterioscler Thromb Vasc Biol 19: 1526-1534, 1999.
42. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43, 2002.
43. Severino C, Brizzi P, Solinas A, Secchi G, Maioli M, Tonolo G. Low-dose dexamethasone in the rat: a model to study insulin resistance. Am J Physiol Endocrinol Metab 283: E367-E373, 2002.
44. Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 246: 142-146, 2006.
45. Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, Comb MJ. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 15: 4629-4642, 1996.
46. Wu Y, Song P, Xu J, Zhang M, Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 282: 9777-9788, 2007.
47. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426, 2003.
48. Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H, Shen X. MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and HSP27. J Biol Chem 281: 37215-37226, 2006.